Autoimmune Diseases Market in the US 2015-2019

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Disease Overview
06.1 Understanding the Disease
06.2 Epidemiology
06.3 Etiology
06.4 Symptoms
06.5 Diagnosis
06.5.1 Medical History
06.5.2 Laboratory examination
06.6 Disease Management
06.7 Quality of Life
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
08. Pipeline Portfolio
08.1 Pipeline Landscape: Crohn's Disease
08.2 Pipeline Landscape: Multiple Sclerosis
08.3 Pipeline Landscape: Systemic Lupus Erythematosus
08.5 Five Forces Analysis
09. Market Segmentation by Type of Diseases
09.1 Ankylosing Spondylitis
09.2 Crohn's Disease
09.3 Multiple Sclerosis
09.4 Psoriasis
09.5 Rheumatoid Arthritis
09.6 Systemic Lupus Erythematosus
10. Market Segmentation by Type of Molecules
10.1.1 Small Molecules
10.1.2 Biologics
11. Market Segmentation by Route of Administration
11.1.1 Parenteral Route
11.1.2 Oral Route
12. Ankylosing Spondylitis Market in the US
12.1 Market Size and Forecast
13. Crohn's Disease Market in the US
13.1 Market Size and Forecast
14. Multiple Sclerosis Market in the US
14.1 Market Size and Forecast
15. Rheumatoid Arthritis Market in the US
15.1 Market Size and Forecast
16. Psoriasis Market in the US
16.1 Market Size and Forecast
17. Systemic Lupus Erythematosus Market in the US
17.1 Market Size and Forecast
18. Buying Criteria
19. Market Growth Drivers
20. Drivers and their Impact
21. Market Challenges
22. Impact of Drivers and Challenges
23. Market Trends
24. Trends and their Impact
25. Vendor Landscape
25.1 Competitive Scenario
25.1.1 Key News
25.1.2 Mergers and Acquisitions
25.2 Market Share Analysis 2014
25.2.1 AbbVie
25.2.2 Janssen Pharmaceuticals
25.2.3 Biogen
25.2.4 Amgen
25.2.5 F. Hoffmann-La Roche
25.3 Other and Future Prominent Vendors
26. Key Vendor Analysis
26.1 AbbVie
26.1.1 Key Facts
26.1.2 Business Overview
26.1.3 Product Segmentation by Revenue 2013
26.1.4 Product Segmentation by Revenue 2012 and 2013
26.1.5 Sales by Geography
26.1.6 Business Strategy
26.1.7 Key Developments
26.1.8 SWOT Analysis
26.2 Amgen
26.2.1 Key Facts
26.2.2 Business Overview
26.2.3 Business Segmentation by Revenue 2013
26.2.4 Product Portfolio by Revenue 2013
26.2.5 Business Segmentation by Revenue 2012 and 2013
26.2.6 Geographical Segmentation by Revenue 2013
26.2.7 Business Strategy
26.2.8 Recent Developments
26.2.9 SWOT Analysis
26.3 Biogen
26.3.1 Key Facts
26.3.2 Business Overview
26.3.3 Business Segmentation by Revenue 2013
26.3.4 Geographical Segmentation by Revenue 2013
26.3.5 Business Strategy
26.3.6 Key Developments
26.3.7 SWOT Analysis
26.4 F. Hoffmann-La Roche
26.4.1 Key Facts
26.4.2 Business Overview
26.4.3 Business Segmentation
26.4.4 Business Segmentation by Revenue 2012 and 2013
26.4.5 Sales by Geography
26.4.6 Business Strategy
26.4.7 Key Information
26.4.8 SWOT Analysis
26.5 Janssen Pharmaceuticals
26.5.1 Key Facts
26.5.2 Business Overview
26.5.3 Recent Developments
26.5.4 SWOT Analysis